Biophan Technologies 

Ticker: BIPH

Press Release Friday After the Bell: Biophan Announces Development of Breakthrough Long-Life Biothermal Battery

Biophan Technologies, Inc., a leading developer of next generation biomedical technology, announced today that it has acquired a majority interest in TE-Bio, LLC, a company developing a breakthrough, long-life power source for use in implanted medical devices, such as pacemakers, defibrillators, neurostimulators, and drug pumps.

The technology is based on a patented innovation in the utilization of thermoelectric materials, using nanoscale-based, thin-film materials to convert thermal energy produced naturally by the human body into electrical energy. The resulting power can be used to "trickle charge" batteries for medium-power devices such as defibrillators, or directly power low-energy devices like pacemakers. The Company will be displaying the technology to over 6,000 healthcare professionals at the NASPE--Heart Rhythm Society's Heart Rhythm 2004 Conference, May 19-22, 2004 in San Francisco, CA.

TE-Bio is developing an implantable power system that has the potential to provide as much as a 30-year life--a five-fold increase in service life compared to existing technology. The technology is anticipated to dramatically extend the service life of neurostimulators and drug pumps that are used for treatment of tremors, diabetes, and chronic pain. Furthermore, since these devices can be implanted in young patients, the combination of TE-Bio technology and extended device life may reduce the number of replacement implants needed throughout a patient's life. For further information or to view the patent, please visit www.biophan.com/biothermal.php.

"The realization of generating enough energy to power a pacemaker, or extend the life of a defibrillator, from the heat differential in our bodies, has been brought within striking distance by the remarkable revolution in materials science and advances in nanotechnology," stated Michael Weiner, CEO of Biophan.

To view the full Press Release please visit http://biz.yahoo.com/bw/040514/145525_1.html

Media Article: Biophan Technologies Acquires Biothermal Battery Developer

Biophan and its licensors have nine issued U.S. patents and over fifty patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, and photonics. Friday's announcement of the acquisition of TE-Bio brings Biophan's patents one notch up on its major competitors whose own batteries require surgical replacement frequently.

To view the full Article please visit http://biz.yahoo.com/iw/040515/067348.html

News Release: Biophan CEO Reaffirms Commitment to Strategic Vision and FY 2005 Growth

Company Addresses Stockholders in Annual Letter Outlining Latest Surge in Corporate Activity 

Biophan Technologies, Inc., a leading developer of next generation biomedical technology, reaffirmed today its unequivocal commitment to its strategic initiatives and outlined its plans for the Company's 2005 fiscal year. Stockholders and other interested parties are invited to view the full text of Biophan's stockholder letter at www.biophan.com/sl.html.

"This past year was a significant one for Biophan on several fronts, and we are very excited about the business opportunities that lie ahead," stated Biophan's CEO, Michael Weiner, in his stockholder letter. "We have formed several key strategic relationships this past year, including with Boston Scientific, that we feel confident will accelerate our growth. In addition, we have solidified existing technology, and developed and/or acquired new technologies that we expect to begin generating revenue in the coming year." 

"Our current operations obviously mirror those of any burgeoning, biomedical technology company, but we truly believe that our time horizon for success is rapidly approaching. Our market is growing virtually on a daily basis, we are getting noticed by key industry players, and we will be announcing what we feel are breakthrough technologies in the coming weeks. All these things are paramount to our success as we move forward." 

To view the full news release please visit http://biz.yahoo.com/bw/040513/135807_1.html

To view the full report, including recent press releases and chart for BIPH please visit http://www.smallcapreview.com/biph.htm

Breakthrough solutions from Biophan Technologies allows millions of pacemaker wearers to safely use MRI diagnosis

MRI (magnetic resonance imaging) is one of the most important diagnostic tools in medicine. But for millions of people around the world who wear implanted medical devices like pacemakers or stents, MRI can not be used.

The problem has been that the strong electromagnetic fields created during the MRI process interfere with the electronics of many implanted devices, endangering the safety of the person wearing it. And safety is not the only concern. Implanted devices as well as many devices used in surgical and diagnostic procedures can also interfere with MRI image quality.

Biophan Technologies has solved these problems. Biophan is developing leading-edge technologies that will make biomedical devices safe and reduce the interference they cause to MRI image quality. As a result, millions of people will now be able to have access to life-saving MRI diagnosis.

Biophan has combined a number of technologies into a filter/coating shielding system that can be easily adopted by pacemaker and medical device manufacturers. And they should be welcomed by manufacturers since there would be little impact on the manufacturing process or on the cost. Biophan??™s technologies can be applied to a wide variety of medical devices including pacemakers, defibrillators, neurostimulators, stents, guide wires, aneurysm clips, biopsy needles and many more.

The market for Biophan??™s technology is large and growing

The medical device market and the MRI market are both well into billions of dollars annually and are enjoying rapid growth. And growth is sure to increase even faster with the arrival of the aging boomer generation. This means that the demand for Biophan??™s technology is large now and will continue to grow larger year after year. To appreciate the size of this market, consider these few facts:

• The number of MRI procedures has increased annually by around 15% with more than 36 million done each year.

• The implanted cardiac device market totals more than $6 billion each year. Add to this the market for other implanted devices and devices used in surgical and diagnostic procedures and the total is well over $10 billion.

•  On a worldwide basis, it is estimated there are over 5 million people with cardiac rhythm implants and approximately 50% are located in the U.S.

•  Approximately 165,000 Americans are currently MRI contraindicated due to some type of cardiac rhythm implant. On a worldwide basis, that number would exceed 300,000.

Plus Biophan enjoys significant patent protection

The foundation for success of a biotech company is its ability to attain patent protection for the technologies it develops. Simply put, patents are a biotech??™s cash cow. In this regard, Biophan has made tremendous progress.

In a recent news release, Biophan announced the allowance of five patents and the issuance of five additional patents. This elevates its total patent portfolio to nine issued patents and six allowed patents plus forty-five patent applications in process.

Biophan plans to build on its success and to continue focusing its resources on technological innovation. It will introduce commercial products through strategic joint ventures and licensing agreements with major companies having marketing and development expertise. And it will ensure success by providing marketing and technical support to its various partners.

In short, for aggressive investors with a long-term outlook, Biophan Technologies is one stock that should be closely examined. Given all of the facts above, the opportunity for share value appreciation seems significant. To learn more about Biophan, please visit www.biophan.com or visit www.SmallCapReview.com/biph.htm.

Disclaimer 

SmallCapReview.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. For continuing coverage of BIPH, please sign up for our free newsletter, SmallCapReview.com News. Information contained in this report was extracted from current documents filed with the SEC, the Company website and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our website. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for the above mentioned company. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. 

Copyright SmallCapReview.com. All rights reserved. SmallCapReview.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our website and individual reports released to the public through this website, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our website or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility, particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our website or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), SmallCapReview.com will disclose in its disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SmallCapReview.com website. SmallCapReview.com has been compensated eleven thousand dollars by a third party for its efforts in presenting the Biophan Technologies profile on its website and distributing it to its database of subscribers. SmallCapReview.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our website and within our reports contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as ???expects??™???, ???will,??? ???anticipates,??? ???estimates, ???believes,??? or that by statements indicating certain actions ???may,??? ???could,??? or ???might??? occur. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. We encourage our readers to invest carefully and read the investor information available at the websites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its website.